Biomanufacturing has the potential to replace petrochemical and animal-based products at scale, but high costs and slow, inefficient scaling have kept it from breaking out beyond pharma. Without a viable way to bring bio-based alternatives to market, industries remain locked into outdated, unsustainable production methods.
Arsenale Bioyards has built the first fully integrated, AI-driven platform that slashes biomanufacturing costs by up to 90%. Its modular Bioyards enable efficient scaling-out instead of expensive scaling-up, making precision fermentation commercially viable across industries like food, cosmetics, and materials.
Arsenale is doing more than optimizing biomanufacturing—it’s transforming it into a scalable, investable asset class. Their approach makes bio-based production cost-competitive, unlocking a $200B+ market and accelerating the transition away from fossil-based industries. Behind this vision is a world-class team with decades of expertise in bioprocessing, machine learning, and scaling industrial operations. Their proven track record and strategic execution give us confidence that they can deliver the innovation precision fermentation desperately needs.
Arsenale Bioyards is redefining biomanufacturing, making it scalable, cost-effective, and a true alternative to petrochemicals and industrial animal farming. Their technology has the potential to drive massive environmental impact: Switching to bio-manufactured proteins can cut GHG emissions by up to 98%, save hundreds of square meters of land per kilogram of protein, and drastically reduce water use. By replacing fossil-based and animal-derived products at scale, Arsenale is paving the way for a bioeconomy that is not only sustainable but also economically competitive.
